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With great interest we read the report by Khan et al. and 
commend the authors on having conducted the CORAL 
trial, which is one of three currently published randomized 
controlled trials (RCTs) reporting on long-term oncological 
outcomes of open (ORC) versus minimal invasive radical 
cystectomy (MIRC) for muscle-invasive bladder cancer 
(MIBC) or high-risk non muscle-invasive bladder cancer 
(HRNMIBC) (1-3). 
Although the main incentive for the introduction of 
MIRC has always been to reduce perioperative morbidity 
and length of hospital stay, the introduction of a new 
surgical technique is only justified if the oncological 
outcomes are equal or better than the current gold 
standard, which is ORC. Following their initial publication 
on perioperative morbidity, Khan et al. recently reported 
the long-term oncological outcomes from their single 
institution randomized controlled trial (RCT) of ORC 
versus laparoscopic (LRC) and robot-assisted radical 
cystectomy (RARC) with extracorporeal urinary diversion in 
a total of 59 MIBC (N=38) or HRNMIBC (N=21) patients 
(1,4). The clinical outcome of the patients did not differ 
between the treatment groups as no statistically significant 
differences were observed in the 5-year recurrence-free 
(RFS), cancer-specific (CSS), and overall survival (OS). The 
5-year RFS was 60%, 58%, and 71%; the 5-year CSS was 
64%, 68%, and 69%; and the 5-year OS was 55%, 65%, 
and 61% for ORC, RARC, and LRC, respectively. These 
findings are in line with the results of two other RCTs by 
Bochner et al. and Venkatramani et al. (2,3) that randomized 
patients between ORC and RARC. In addition, the 5-year 
CSS rate observed in the CORAL trial was equivalent to 
the 5-year CSS of 66.8% reported by Hautmann et al. in a 
cohort of 1,100 patients treated by ORC (5). These survival 
data support the evidence that MIRC is comparable to open 
surgery in terms of oncological outcomes. 
The authors should be commended on their study design 
with well-matched study arms, adequate patient follow-
up, and their efforts to prevent surgeon bias. Although 
an RCT represents a high level of evidence, even RCTs 
might be influenced by several biases and the CORAL 
trial is not exempt. Important limitations of the study 
are the small sample size, the single center set-up, and 
failure to deliver treatment to the allocated randomized 
treatment arms. In the ORC arm, all 20 patients underwent 
the allocated treatment whereas in the RARC group one 
patient underwent conversion to ORC and in the LRC 
group 5 patients (25%) did not receive LRC; three patients 
were converted to RARC, one to ORC and one patient 
underwent chemoradiation instead of surgery. Additionally, 
the CORAL trial was powered to detect a difference in 
perioperative complication rates between the studies arms 
and not to test differences in survival outcomes. Moreover, 
because of recruitment difficulties, the trial was terminated 
early after inclusion of 60 instead of the aimed 141 patients. 
Therefore, reported results should be interpreted with great 
caution.
The proportion of patients who received neoadjuvant 
chemotherapy in the CORAL trial was small (N=6) but 
equally distributed between the study arms in three, two 
and one patient for ORC, RARC and LRC respectively. 
The clinical lymph node status was not reported and 
the indication for preoperative chemotherapy, either 
being neoadjuvant for clinically node-negative patients 
or induction setting for clinically node-positive patients, 
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was not stated. This could possibly have had an impact on 
oncological survival outcomes. Moreover, the proportion 
of preoperative MIBC diagnosis seemed overrepresented in 
the LRC group; 74% versus 60% in both ORC and RARC 
groups. 
With respect to the oncological safety of MIRC vs. ORC, 
two important points of discussion have been mentioned 
over recent years. First, it was suggested that lymph node 
dissections were less adequate and resulted in a lower lymph 
node yield for minimally invasive techniques. Secondly, 
concerns were raised that the pneumoperitoneum during 
laparoscopic surgery could enhance local tumor spread or 
implantation of tumor cells into the peritoneal cavity (2,6). 
However, like the RAZOR trial, Khan et al. did not find a 
difference in lymph node yield and local recurrence rate 
between the different surgical modalities (1,3).
Lastly, both patient and surgeon bias were also noted in 
the CORAL trial. Of the 164 patients eligible for inclusion, 
35% declined to participate because of patient preferences 
for a specific surgical approach. The authors tried to 
minimize surgeon bias by ensuring all surgeons completed 
their learning curve with more than 110 cystectomies 
performed per surgeon for the respective modalities 
but evidence is lacking on what the optimal number 
of procedures performed should be for a surgeon who 
completed the learning curve. Therefore, differences in 
surgical skills could potentially have influenced the results 
of the CORAL trial. 
Current literature suggests that oncological outcomes for 
MIBC are predominantly determined by tumor biology and 
that the surgical modality is unlikely to play a significant 
role in the risk of disease recurrence after cystectomy. 
Therefore, the advantage of MIRC over ORC should lay 
in less perioperative morbidity because cystectomy itself is 
a challenging surgical procedure with high morbidity rates. 
In addition, reduction of perioperative morbidity lowers 
additional costs of auxiliary diagnostic and therapeutic 
procedures for peri- and postoperative complications. 
Thus far, in all RCTs that compared ORC versus MIRC 
the urinary diversion was done extracorporeal. However, 
since morbidity from a cystectomy is mainly caused by 
the reconstructive phase for which parts of the small 
intestine are used, extracorporeal urinary diversions 
for which a laparotomy is mandatory could dilute the 
potential advantage of MIRC and open reconstruction in 
terms of perioperative morbidity. We therefore eagerly 
await results of the iROC study, a multicenter prospective 
RCT comparing RARC with intracorporeal urinary 
diversion versus ORC (7). Furthermore, minimally invasive 
techniques provide an important advantage because the 
pneumoperitoneum and superior visibility of small blood 
vessels lead to reduced perioperative blood loss and the need 
for blood transfusions. Also, the median length of hospital 
stay is shorter for MIRC than for ORC, while ORC shows 
a reduced operating time and lower total costs. 
Taken together, no differences have been observed 
between MIRC and ORC in terms of complication rate, 
pathological stage, lymph node yield and positive surgical 
margins. Now multiple RCTs, including the CORAL trial, 
show that long-term oncological outcomes are equivalent 
for MIRC and ORC and that perioperative morbidity 
is favorable for MIRC. Are these benefits of MIRC, as 
part of a larger context of complete patient recovery over 
time, sufficient to change current clinical practice? The 
surgical technique is one aspect of the complete treatment 
of MIBC and up to now no solid evidence is provided that 
minimal invasive techniques strongly outweigh the gold 
standard ORC in terms of costs, perioperative and long-
term oncological outcome. Furthermore, patient and tumor 
characteristics should not be neglected and surgeon and 
hospital volume are well-established key determinants of 
outcome for both techniques. By developing minimally 
invasive techniques, we have broadened our surgical 
repertoire and are now able to offer patients a more 
personalized treatment option. Hence, for us the challenge 
does not lie in identifying the superiority of one surgical 
technique over the other, but rather in the imperative 
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